Drug intelligence / Profile preview

Hailun Capsule

Development stage: Unknown
Lead developer: Inner Mongolia University for Nationalities
Modality: Small Molecules
Administration: Oral

Overview

Hailun Capsule is a Mongolian traditional medicine (MTM) developed by the Mongolian Medicine College of Inner Mongolia University for Nationalities. It is primarily investigated for the treatment of ischemic stroke during the early recovery phase, specifically for patients presenting with blood stasis blocking collaterals syndrome. As a traditional preparation, it is designed to promote blood circulation, resolve blood stasis, and clear the meridians and collaterals to improve neurological function following a cerebral infarction. The drug has been evaluated in Phase II clinical trials in China to assess its safety and efficacy in patients with large-artery atherosclerosis in the anterior circulation.

Brand names: Hailun Capsule
Other names: Hailun海伦胶囊

Beyond the preview

Go deeper on Hailun Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hailun Capsule.

Explore the full profile